In latest cancer deal, Bristol Myers Squibb's new BD chief bets $65M in search for more targets like PARP
Elizabeth Mily, the new chief of the strategy and business development group at Bristol Myers Squibb, has struck her first high-profile collaboration since
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.